ATE363074T1 - Substrate und screeningverfahren für transportproteine - Google Patents
Substrate und screeningverfahren für transportproteineInfo
- Publication number
- ATE363074T1 ATE363074T1 AT00966735T AT00966735T ATE363074T1 AT E363074 T1 ATE363074 T1 AT E363074T1 AT 00966735 T AT00966735 T AT 00966735T AT 00966735 T AT00966735 T AT 00966735T AT E363074 T1 ATE363074 T1 AT E363074T1
- Authority
- AT
- Austria
- Prior art keywords
- transport proteins
- substrates
- screening methods
- methods
- screening
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15407199P | 1999-09-14 | 1999-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE363074T1 true ATE363074T1 (de) | 2007-06-15 |
Family
ID=22549879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00966735T ATE363074T1 (de) | 1999-09-14 | 2000-09-14 | Substrate und screeningverfahren für transportproteine |
Country Status (6)
Country | Link |
---|---|
US (2) | US7413536B1 (de) |
EP (1) | EP1212619B1 (de) |
AT (1) | ATE363074T1 (de) |
AU (1) | AU7703400A (de) |
DE (1) | DE60034954D1 (de) |
WO (1) | WO2001020331A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2405151A1 (en) * | 2000-04-07 | 2001-10-18 | University Of Maryland, Baltimore | Bile acid containing prodrugs with enhanced bioavailability |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
EP1361847A2 (de) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Gallensäurekonjugate zur bereitstellung anhaltender systemischer arneimittelkonzentrationen |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
WO2002100172A1 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Administration of agents via the pept-2 transporter |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100344A2 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
NZ535354A (en) | 2002-02-15 | 2008-01-31 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
AU2003253058A1 (en) | 2002-05-31 | 2003-12-19 | Commissariat A L'energie Atomique | Method of screening groups of radioactive molecules and applications thereof |
FR2840994B1 (fr) * | 2003-01-22 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
FR2840407B1 (fr) * | 2002-05-31 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US20040161424A1 (en) * | 2002-10-08 | 2004-08-19 | Xenoport | Human organic solute transporters |
AU2003291726A1 (en) | 2002-11-04 | 2004-06-07 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
WO2005075992A1 (en) * | 2004-01-30 | 2005-08-18 | Xenoport, Inc. | Mct1 transporter expressed in blood brain barrier cells |
UA88008C2 (en) * | 2004-04-09 | 2009-09-10 | Чугей Сейяку Кабусики Кайся | Water-soluble prodrugs |
WO2006017352A1 (en) | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
US7241807B2 (en) | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
EP1928822B1 (de) | 2005-09-26 | 2013-02-27 | Life Technologies Corporation | Durch violette laser anregbare farbstoffe und verfahren zu ihrer anwendung |
EP1982177A1 (de) * | 2006-01-31 | 2008-10-22 | Sanofi-Aventis | Verfahren zur bestimmung der aktivität des organischen kationentransporters |
WO2007098037A2 (en) * | 2006-02-17 | 2007-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sequential reporter enzyme luminescence (srl) methods and compositions for practicing the same |
WO2007119774A1 (ja) | 2006-04-13 | 2007-10-25 | Chugai Seiyaku Kabushiki Kaisha | タウリントランスポーター遺伝子 |
US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
CA2671850A1 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
US20100233759A1 (en) | 2007-03-15 | 2010-09-16 | Chugai Seiyaku Kabushiki Kaisha | Method for production of polypeptide |
AU2008284753B2 (en) | 2007-08-07 | 2014-01-16 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous protein |
JP5337043B2 (ja) | 2007-10-15 | 2013-11-06 | 中外製薬株式会社 | 異種タンパク質を高生産する細胞の作製方法 |
BRPI0818764B1 (pt) * | 2007-10-24 | 2017-11-21 | Chugai Seiyaku Kabushiki Kaisha | Process of production of a polipeptídeo |
US20120058937A9 (en) * | 2008-04-15 | 2012-03-08 | Tsrl, Inc. | Prodrugs of Neuraminidase Inhibitors |
EA021797B1 (ru) | 2009-02-13 | 2015-09-30 | Икс-Чем, Инк. | Способы создания и скрининга библиотек, кодируемых днк |
CA2752622A1 (en) * | 2009-02-13 | 2010-08-19 | X-Body, Inc. | Identification of nucleic acid delivery vehicles using dna display |
US8741601B2 (en) | 2009-04-22 | 2014-06-03 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell capable of high-yield production of heteroproteins |
KR101809758B1 (ko) * | 2009-07-16 | 2017-12-15 | 베크만 컬터, 인코포레이티드 | 신규 형광 염료 및 그의 용도 |
JP5561692B2 (ja) * | 2010-03-09 | 2014-07-30 | 国立大学法人群馬大学 | 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法 |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
US8399262B2 (en) | 2011-03-23 | 2013-03-19 | Darrel A. Mazzari | Biosensor |
BR112014005205A2 (pt) | 2011-09-07 | 2017-03-21 | X-Chem Inc | métodos para etiquetar bibliotecas codificadas com dna |
EP3278796A1 (de) | 2011-10-28 | 2018-02-07 | Lumena Pharmaceuticals LLC | Gallensäurerückflusshemmer zur behandlung von hypercholämie und cholestatischer lebererkrankung |
EP3266457A1 (de) | 2011-10-28 | 2018-01-10 | Lumena Pharmaceuticals LLC | Gallensäurerückflusshemmer zur behandlung von cholestase-erkrankungen im kindesalter |
NZ739931A (en) | 2012-07-13 | 2019-08-30 | X Chem Inc | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
BR112015023646A2 (pt) | 2013-03-15 | 2017-07-18 | Lumena Pharmaceuticals Inc | inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino |
CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
WO2017100376A2 (en) | 2015-12-07 | 2017-06-15 | Zymergen, Inc. | Promoters from corynebacterium glutamicum |
US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
KR102345899B1 (ko) | 2016-06-30 | 2021-12-31 | 지머젠 인코포레이티드 | 박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도 |
JP2019519241A (ja) * | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | グルコース透過酵素ライブラリーを生成するための方法およびその使用 |
GB2552460A (en) | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
CN114072153A (zh) | 2019-02-12 | 2022-02-18 | 米鲁姆制药公司 | 用于治疗胆汁淤积的方法 |
EP4011899A4 (de) * | 2019-08-06 | 2022-09-28 | Huang, Qiang | Deoxycholsäureverbindungen, pharmazeutische zusammensetzungen und verwendungen davon |
CA3157995A1 (en) | 2019-10-25 | 2021-04-29 | Cercacor Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5569678A (en) | 1989-07-31 | 1996-10-29 | Massachusetts Institute Of Technology | Control of wound scar production |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
US5866123A (en) | 1990-04-13 | 1999-02-02 | Research Development Foundation | Gene encoding cationic amino acid transporter protein |
US5236902A (en) | 1990-11-26 | 1993-08-17 | The Governors Of The University Of Alberta | Method and probes for detecting nucleoside transporter and method for producing the probes |
US5580775A (en) | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
DE4222315A1 (de) | 1992-07-05 | 1994-01-13 | Inst Genbiologische Forschung | DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
US5658782A (en) | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
DE4343527A1 (de) | 1993-12-16 | 1995-06-22 | Schering Ag | Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung |
US5589358A (en) | 1993-12-29 | 1996-12-31 | Univ Wake Forest | Ileal bile acid transporter compositions and methods |
US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
AU3927795A (en) * | 1994-11-12 | 1996-06-06 | Basf Aktiengesellschaft | Process for preparing amines from compounds with at least 3 cyano groups |
AU723619B2 (en) * | 1995-04-24 | 2000-08-31 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
EP0773441B1 (de) | 1995-09-11 | 2000-08-02 | La Jolla Cancer Research Foundation | Moleküle, die sich in ausgewählten Organen oder Geweben invivo Einfinden und Verfahren zu ihrer Identifizierung |
EP1281718A3 (de) | 1995-11-10 | 2005-01-19 | ELAN CORPORATION, Plc | Peptiden die den Transport über Geweben erhöhen |
US5780264A (en) | 1996-06-06 | 1998-07-14 | The President And Fellows Of Harvard College | Iron transport protein |
EP0923603A1 (de) | 1996-07-16 | 1999-06-23 | Novo Nordisk A/S | Oligopeptid-transporter |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
ATE268008T1 (de) | 1997-02-27 | 2004-06-15 | Cellomics Inc | Ein system zur zellbasierten reihenuntersuchung |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
AU755154B2 (en) | 1997-05-15 | 2002-12-05 | Cytogen Corporation | Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods |
JP4044728B2 (ja) | 1997-07-15 | 2008-02-06 | メディクエスト セラピューティックス インク | 治療および診断薬剤としての新規なポリアミンアナログ |
-
2000
- 2000-09-14 DE DE60034954T patent/DE60034954D1/de not_active Expired - Lifetime
- 2000-09-14 US US09/661,927 patent/US7413536B1/en not_active Expired - Fee Related
- 2000-09-14 EP EP00966735A patent/EP1212619B1/de not_active Expired - Lifetime
- 2000-09-14 AU AU77034/00A patent/AU7703400A/en not_active Abandoned
- 2000-09-14 AT AT00966735T patent/ATE363074T1/de not_active IP Right Cessation
- 2000-09-14 WO PCT/US2000/025439 patent/WO2001020331A1/en active IP Right Grant
-
2008
- 2008-07-14 US US12/172,801 patent/US20090221442A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1212619B1 (de) | 2007-05-23 |
EP1212619A1 (de) | 2002-06-12 |
AU7703400A (en) | 2001-04-17 |
WO2001020331A9 (en) | 2002-10-03 |
WO2001020331A1 (en) | 2001-03-22 |
DE60034954D1 (de) | 2007-07-05 |
EP1212619A4 (de) | 2004-12-08 |
US20090221442A1 (en) | 2009-09-03 |
US7413536B1 (en) | 2008-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE363074T1 (de) | Substrate und screeningverfahren für transportproteine | |
DE60232688D1 (de) | Grenzflächen-biomaterialien | |
NO20043259L (no) | Bindingsproteiner som biosensorer | |
GB2451042A (en) | Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals | |
ATE295347T1 (de) | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen | |
DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
EP1687283A4 (de) | Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung | |
DE60005787D1 (de) | Wasserlösliche rhodaminfarbstoffe und ihre konjugate | |
NO20043257D0 (no) | Innkapslede bindingsproteiner som biosensorer | |
ATE294164T1 (de) | Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening | |
DK0921857T3 (da) | Flerbröndsplader med lav baggrund til fluorescensmålinger af biologiske og biokemiske pröver | |
DE60126337D1 (de) | Verfahren zum screenen für gpr40-liganden | |
TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
DE69912839D1 (de) | Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung | |
WO2002063271A8 (en) | Activity based probe analysis | |
ITRM980303A0 (it) | Composizione contenente radioisotopi immobilizzati su particelle solide utile in particolare per la biancheria clinica in patologie | |
DK1017684T3 (da) | Kontrastmiddel til afbildning af infarkter og nekroser | |
WO1999050459A3 (en) | High throughput in vitro screening assays for transcription modulators | |
RS20100249A (en) | CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE | |
WO2003008635A8 (en) | η-SECRETASE IN VITRO SCREENING ASSAY | |
MXPA03001536A (es) | (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen. | |
ATE252574T1 (de) | Benzofuran-2-ones als färbemittel für organische materialien | |
ATE501274T1 (de) | Cucurbiturilderivat-gebundenes feststoffsubstrat und biochip unter verwendung davon | |
ATE256120T1 (de) | Reagentien für cyp2d fluoreszenztest | |
MXPA04004018A (es) | Metodos de separacion por exclusion para toxicidad de compuestos de prueba. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |